Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Study sponsor: Verastem, Inc. · VSTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-06-19Actual
Enrollment · participants35Actual
Source updated2024-02-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.